

# Minutes of the HPRA Leadership Team

## Licensing and regulation section

---

- 17 January 2025 at 9.30
- Hybrid Teams call and CEO's meeting room 3<sup>rd</sup> floor

Chair	Present	Apologies
Dr Lorraine Nolan, Chief Executive	Ms R. Purcell, Deputy Chief Executive	Ms E. Stuart, Director of Human Resources and Development*
	Ms G. Power, Director of Compliance	
	Dr N. MacAleenan, Director of Medical Devices	
	Dr J.G Beechinor, Director of Veterinary Science	
	Ms S. Curran, Director of Human Products Monitoring	
	Dr F. Lonsdale, Director of Human Medicines	
	Mr S. d'Art, Director of ICT and Business Services	

- Minutes taken by Ms K. Murphy, Secretary to the Committee
- Please note that certain information, such as personal data, confidential/commercially sensitive information, and pending prosecutions may have been removed from these minutes
- \*Approved via written procedure
- \*\*Attended part of the meeting

### 1 ADOPTON OF THE AGENDA

The meeting adopted the agenda.

### 2 DECLARATIONS OF INTEREST

There was nothing to report.

### **3 ADOPTION OF THE MINUTES OF THE LAST MEETING**

The minutes of the meeting of 10 January were adopted and signed.

### **4 MATTERS ARISING**

There was nothing to report.

### **5 PUBLIC HEALTH ISSUES**

#### **5.1 PRAC highlights**

An update on the January PRAC meeting was provided.

### **6 PRODUCT ISSUES**

There was nothing to report.

### **7 REJECTIONS, SUSPENSIONS AND REVOCATIONS**

There was nothing to report.

### **8 LICENSING TABLES**

The attached tables were approved.

### **9 AOB**

#### **9.1 S.I. No. 752/2024 - Data Protection Act 2018 (Control of Data for the Inquiry into the Historical Licensing and Use of Sodium Valproate) Regulations 2024**

HLT noted the signing of the above statutory instruments by the Minister on 23 December 2024.

#### **9.2 Article 51 referral case A5155393**

The HLT discussed the case and concluded that in this case, rule 14 would not apply and so class IIb in accordance with rule 4 is appropriate.

#### **9.3 Low dose codeine containing products**

Next steps in the ongoing classification review for all low dose codeine containing products were discussed.